Conflicting results from clinical observations and murine models: what is the role of plasminogen activators in tumor growth?
Narazaki
Masashi
M
Tosato
Giovanna
G
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001713:Biphenyl Compounds; D002403:Cathepsins / Q000378:metabolism; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000378:metabolism*; D051379:Mice; D009369:Neoplasms / Q000378:metabolism* / Q000473:pathology*; D009930:Organic Chemicals / Q000494:pharmacology; D010654:Phenylbutyrates; D010960:Plasminogen Activators / Q000378:metabolism*; D015849:Plasminogen Inactivators / Q000378:metabolism; D011237:Predictive Value of Tests; D011379:Prognosis; D019714:Tissue Inhibitor of Metalloproteinases / Q000378:metabolism; D017211:Treatment Failure; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D001713:Biphenyl Compounds; D004791:Enzyme Inhibitors; D061965:Matrix Metalloproteinase Inhibitors; D009930:Organic Chemicals; D010654:Phenylbutyrates; D015849:Plasminogen Inactivators; D019714:Tissue Inhibitor of Metalloproteinases; C113281:Bay 12-9566; D002403:Cathepsins; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator; D020782:Matrix Metalloproteinases